vs
Side-by-side financial comparison of HANMI FINANCIAL CORP (HAFC) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
Travere Therapeutics, Inc. is the larger business by last-quarter revenue ($129.7M vs $71.2M, roughly 1.8× HANMI FINANCIAL CORP). On growth, Travere Therapeutics, Inc. posted the faster year-over-year revenue change (73.4% vs 17.1%). Over the past eight quarters, Travere Therapeutics, Inc.'s revenue compounded faster (77.0% CAGR vs 10.4%).
Hanmi Bank Corporation is a community bank headquartered in Los Angeles, California, with 35 branches and eight loan production offices in California, Texas, Illinois, New York, New Jersey and Virginia.
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
HAFC vs TVTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $71.2M | $129.7M |
| Net Profit | $21.2M | — |
| Gross Margin | — | 98.0% |
| Operating Margin | 29.8% | -25.0% |
| Net Margin | 29.8% | — |
| Revenue YoY | 17.1% | 73.4% |
| Net Profit YoY | 20.0% | — |
| EPS (diluted) | $0.70 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $71.2M | $129.7M | ||
| Q3 25 | $71.0M | $164.9M | ||
| Q2 25 | $65.2M | $114.4M | ||
| Q1 25 | $62.8M | $81.7M | ||
| Q4 24 | $60.8M | $74.8M | ||
| Q3 24 | $58.5M | $62.9M | ||
| Q2 24 | $56.7M | $54.1M | ||
| Q1 24 | $58.4M | $41.4M |
| Q4 25 | $21.2M | — | ||
| Q3 25 | $22.1M | $25.7M | ||
| Q2 25 | $15.1M | $-12.8M | ||
| Q1 25 | $17.7M | $-41.2M | ||
| Q4 24 | $17.7M | — | ||
| Q3 24 | $14.9M | $-54.8M | ||
| Q2 24 | $14.5M | $-70.4M | ||
| Q1 24 | $15.2M | $-136.1M |
| Q4 25 | — | 98.0% | ||
| Q3 25 | — | 99.0% | ||
| Q2 25 | — | 98.7% | ||
| Q1 25 | — | 94.3% | ||
| Q4 24 | — | 96.6% | ||
| Q3 24 | — | 97.4% | ||
| Q2 24 | — | 96.2% | ||
| Q1 24 | — | 96.4% |
| Q4 25 | 29.8% | -25.0% | ||
| Q3 25 | 31.1% | 15.1% | ||
| Q2 25 | 23.2% | -11.1% | ||
| Q1 25 | 28.1% | -52.2% | ||
| Q4 24 | 29.1% | -81.2% | ||
| Q3 24 | 25.5% | -89.3% | ||
| Q2 24 | 25.5% | -125.1% | ||
| Q1 24 | 26.0% | -336.5% |
| Q4 25 | 29.8% | — | ||
| Q3 25 | 31.1% | 15.6% | ||
| Q2 25 | 23.2% | -11.1% | ||
| Q1 25 | 28.1% | -50.4% | ||
| Q4 24 | 29.1% | — | ||
| Q3 24 | 25.5% | -87.1% | ||
| Q2 24 | 25.5% | -130.1% | ||
| Q1 24 | 26.0% | -328.9% |
| Q4 25 | $0.70 | $0.04 | ||
| Q3 25 | $0.73 | $0.28 | ||
| Q2 25 | $0.50 | $-0.14 | ||
| Q1 25 | $0.58 | $-0.47 | ||
| Q4 24 | $0.58 | $-0.71 | ||
| Q3 24 | $0.49 | $-0.70 | ||
| Q2 24 | $0.48 | $-0.91 | ||
| Q1 24 | $0.50 | $-1.76 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $93.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $796.4M | $114.8M |
| Total Assets | $7.9B | $605.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $93.0M | ||
| Q3 25 | — | $110.9M | ||
| Q2 25 | — | $75.2M | ||
| Q1 25 | — | $61.9M | ||
| Q4 24 | — | $58.5M | ||
| Q3 24 | — | $36.4M | ||
| Q2 24 | — | $32.3M | ||
| Q1 24 | — | $43.3M |
| Q4 25 | $796.4M | $114.8M | ||
| Q3 25 | $779.5M | $73.6M | ||
| Q2 25 | $762.8M | $32.7M | ||
| Q1 25 | $751.5M | $32.8M | ||
| Q4 24 | $732.2M | $59.1M | ||
| Q3 24 | $736.7M | $-30.5M | ||
| Q2 24 | $707.1M | $15.1M | ||
| Q1 24 | $703.1M | $74.1M |
| Q4 25 | $7.9B | $605.2M | ||
| Q3 25 | $7.9B | $538.6M | ||
| Q2 25 | $7.9B | $555.3M | ||
| Q1 25 | $7.7B | $548.8M | ||
| Q4 24 | $7.7B | $594.1M | ||
| Q3 24 | $7.7B | $504.4M | ||
| Q2 24 | $7.6B | $551.1M | ||
| Q1 24 | $7.5B | $663.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $206.0M | $60.7M |
| Free Cash FlowOCF − Capex | $203.7M | — |
| FCF MarginFCF / Revenue | 286.2% | — |
| Capex IntensityCapex / Revenue | 3.2% | — |
| Cash ConversionOCF / Net Profit | 9.70× | — |
| TTM Free Cash FlowTrailing 4 quarters | $356.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $206.0M | $60.7M | ||
| Q3 25 | $146.9M | $14.3M | ||
| Q2 25 | $-19.0M | $5.0M | ||
| Q1 25 | $25.8M | $-42.2M | ||
| Q4 24 | $52.6M | $-35.7M | ||
| Q3 24 | $6.7M | $-42.5M | ||
| Q2 24 | $2.1M | $-40.2M | ||
| Q1 24 | $30.0M | $-119.0M |
| Q4 25 | $203.7M | — | ||
| Q3 25 | $146.4M | $14.2M | ||
| Q2 25 | $-19.6M | — | ||
| Q1 25 | $25.6M | — | ||
| Q4 24 | $49.9M | — | ||
| Q3 24 | $6.5M | — | ||
| Q2 24 | $1.3M | $-40.3M | ||
| Q1 24 | $29.2M | — |
| Q4 25 | 286.2% | — | ||
| Q3 25 | 206.3% | 8.6% | ||
| Q2 25 | -30.0% | — | ||
| Q1 25 | 40.7% | — | ||
| Q4 24 | 82.1% | — | ||
| Q3 24 | 11.1% | — | ||
| Q2 24 | 2.3% | -74.5% | ||
| Q1 24 | 50.0% | — |
| Q4 25 | 3.2% | — | ||
| Q3 25 | 0.8% | 0.1% | ||
| Q2 25 | 0.9% | — | ||
| Q1 25 | 0.4% | — | ||
| Q4 24 | 4.3% | — | ||
| Q3 24 | 0.4% | 0.0% | ||
| Q2 24 | 1.4% | 0.2% | ||
| Q1 24 | 1.4% | 0.0% |
| Q4 25 | 9.70× | — | ||
| Q3 25 | 6.66× | 0.56× | ||
| Q2 25 | -1.26× | — | ||
| Q1 25 | 1.46× | — | ||
| Q4 24 | 2.97× | — | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | 0.14× | — | ||
| Q1 24 | 1.98× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HAFC
Segment breakdown not available.
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
